Demographic and clinical characteristics of patients in the comparative analysis set
| . | SCHOLAR-5 before weighting (n = 143) . | ZUMA-5 (n = 86) . | Weighted SCHOLAR-5 (n = 85) . | Weighted SMD . |
|---|---|---|---|---|
| Median age* (range) | 64 (36-89) | 62 (34-79) | 61 (36-89) | 0.04 |
| Male, n (%) | 81 (56.6%) | 48 (55.8%) | 53 (61.9%) | 0.12 |
| Median size of largest nodal mass* (IQR), cm | 4.2 (2.8-6.5) | 4.4 (3.3-6.4) | 4.0 (2.9-6.3) | 0.09 |
| FL subtype, n (%) | ||||
| Grade 1 | 56 (42.4) | 20 (23.3) | 30 (37.3) | 0.54 |
| Grade 2 | 61 (46.2) | 43 (50) | 42 (52.6) | |
| Grade 3a | 15 (11.4) | 23 (26.7) | 8 (10.1) | |
| Missing | 11 | 0 | 5 | |
| Median number of prior lines of therapy (range) | 2 (2-8) | 3 (2-9) | 3 (2-8) | 0.05 |
| Median time since last treatment* (IQR), mo | 6.8 (1.2-22.7) | 3.5 (1.8-9.0) | 2.3 (0.7-8.0) | 0.06 |
| Response to prior line of therapy,* n (%) | ||||
| CR | 41 (28.7) | 23.01 (26.8) | 19 (22.8) | 0.07 |
| PR | 49 (34.3) | 19.34 (22.5) | 19 (22.4) | |
| SD | 22 (15.4) | 24.15 (28.1) | 26 (31.2) | |
| PD | 31 (21.7) | 19.5 (22.7) | 20 (23.5) | |
| Refractory to prior LoT,* n (%) | 87 (60.6) | 63 (73.3) | 65 (76.6) | 0.08 |
| POD24*, n (%) | 51 (35.7) | 49 (57.0) | 47 (55.9) | 0.02 |
| Prior stem cell transplant,* n (%) | 31 (21.7) | 21 (24.4) | 24 (28.0) | 0.08 |
| Median time since diagnosis (IQR), mo | 84.8 (53.0-130.5) | 59.9 (35.-96.6) | 64.6 (41.0-115.8) | 0.10 |
| Disease stage, n (%) | ||||
| I | 4 (6.2) | 2 (2.3) | 1 (4.6) | NE |
| II | 2 (3.1) | 9 (10.5) | 0 (1.3) | |
| III | 17 (26.2) | 35 (40.7) | 8 (27.0) | |
| IV | 42 (64.6) | 40 (46.5) | 20 (67.1) | |
| Missing | 78 | 0 | 55 | |
| Number of nodal sites, n (%) | ||||
| 1 | 14 (15.1) | 16 (22.5) | 8 (14.1) | NE |
| 2 | 17 (18.3) | 12 (16.9) | 13 (21.5) | |
| 3 | 9 (9.7) | 7 (9.9) | 7 (10.9) | |
| >4 | 53 (57) | 36 (50.7) | 32 (53.6) | |
| Missing | 50 | 15 | 25 (29.4) | |
| FLIPI, n (%) | ||||
| 0 | 2 (4) | 3 (3.5) | 0 (0.4) | NE |
| 1 | 4 (8) | 10 (11.6) | 2 (9.5) | |
| 2 | 11 (22) | 33 (38.4) | 4 (17.4) | |
| 3 | 19 (38) | 25 (29.1) | 7 (32.8) | |
| 4 | 10 (20) | 12 (14.0) | 6 (28.1) | |
| 5 | 4 (8) | 3 (3.5) | 3 (11.7) | |
| Missing | 93 | 0 | 62 |
| . | SCHOLAR-5 before weighting (n = 143) . | ZUMA-5 (n = 86) . | Weighted SCHOLAR-5 (n = 85) . | Weighted SMD . |
|---|---|---|---|---|
| Median age* (range) | 64 (36-89) | 62 (34-79) | 61 (36-89) | 0.04 |
| Male, n (%) | 81 (56.6%) | 48 (55.8%) | 53 (61.9%) | 0.12 |
| Median size of largest nodal mass* (IQR), cm | 4.2 (2.8-6.5) | 4.4 (3.3-6.4) | 4.0 (2.9-6.3) | 0.09 |
| FL subtype, n (%) | ||||
| Grade 1 | 56 (42.4) | 20 (23.3) | 30 (37.3) | 0.54 |
| Grade 2 | 61 (46.2) | 43 (50) | 42 (52.6) | |
| Grade 3a | 15 (11.4) | 23 (26.7) | 8 (10.1) | |
| Missing | 11 | 0 | 5 | |
| Median number of prior lines of therapy (range) | 2 (2-8) | 3 (2-9) | 3 (2-8) | 0.05 |
| Median time since last treatment* (IQR), mo | 6.8 (1.2-22.7) | 3.5 (1.8-9.0) | 2.3 (0.7-8.0) | 0.06 |
| Response to prior line of therapy,* n (%) | ||||
| CR | 41 (28.7) | 23.01 (26.8) | 19 (22.8) | 0.07 |
| PR | 49 (34.3) | 19.34 (22.5) | 19 (22.4) | |
| SD | 22 (15.4) | 24.15 (28.1) | 26 (31.2) | |
| PD | 31 (21.7) | 19.5 (22.7) | 20 (23.5) | |
| Refractory to prior LoT,* n (%) | 87 (60.6) | 63 (73.3) | 65 (76.6) | 0.08 |
| POD24*, n (%) | 51 (35.7) | 49 (57.0) | 47 (55.9) | 0.02 |
| Prior stem cell transplant,* n (%) | 31 (21.7) | 21 (24.4) | 24 (28.0) | 0.08 |
| Median time since diagnosis (IQR), mo | 84.8 (53.0-130.5) | 59.9 (35.-96.6) | 64.6 (41.0-115.8) | 0.10 |
| Disease stage, n (%) | ||||
| I | 4 (6.2) | 2 (2.3) | 1 (4.6) | NE |
| II | 2 (3.1) | 9 (10.5) | 0 (1.3) | |
| III | 17 (26.2) | 35 (40.7) | 8 (27.0) | |
| IV | 42 (64.6) | 40 (46.5) | 20 (67.1) | |
| Missing | 78 | 0 | 55 | |
| Number of nodal sites, n (%) | ||||
| 1 | 14 (15.1) | 16 (22.5) | 8 (14.1) | NE |
| 2 | 17 (18.3) | 12 (16.9) | 13 (21.5) | |
| 3 | 9 (9.7) | 7 (9.9) | 7 (10.9) | |
| >4 | 53 (57) | 36 (50.7) | 32 (53.6) | |
| Missing | 50 | 15 | 25 (29.4) | |
| FLIPI, n (%) | ||||
| 0 | 2 (4) | 3 (3.5) | 0 (0.4) | NE |
| 1 | 4 (8) | 10 (11.6) | 2 (9.5) | |
| 2 | 11 (22) | 33 (38.4) | 4 (17.4) | |
| 3 | 19 (38) | 25 (29.1) | 7 (32.8) | |
| 4 | 10 (20) | 12 (14.0) | 6 (28.1) | |
| 5 | 4 (8) | 3 (3.5) | 3 (11.7) | |
| Missing | 93 | 0 | 62 |
FLIPI, Follicular Lymphoma International Prognostic Index; IQR, interquartile range; NE, not evaluable; PD, progressive disease; PR, partial response; SD, stable disease, SMD; standardized mean difference.
Variables used in PS weighting. The SMD for disease stage, number of nodal sites, and FLIPI were not evaluable due to missing data. See supplemental Table 5 for the SMD values before weighting.